Patients with hereditary C1 inhibitor deficiency are at increased risk of angioedema attacks when exposed to known triggers. Upcoming invasive dental or medical procedures, surgical interventions, and significant stressful life events all constitute situations where short-term prophylaxis is indicated to reduce that risk.
The management strategy in this setting centres on short-term prophylaxis given in advance of the anticipated stressor. Both a plasma-derived C1 inhibitor product and an anabolic androgen represent recognised options — the specific choice, timing, and full dosing details are contained in the structured regimen.
DOI: 10.1016/j.jaip.2020.08.046
Short-term prophylaxis is indicated when patients are at increased risk of having an attack associated with known triggers such as invasive dental or medical procedures or stressful life events.
Short-term prophylaxis can be either a single dose of pdC1INH or a course of anabolic androgen.
View source ↗